Compare Biogen Inc (BIIB) vs Carnival Corp (CCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Carnival Corp — how do they compare? Biogen Inc trades at $210 (market cap $30.86B), while Carnival Corp trades at $28.45 (market cap $37.90B). The key difference: Carnival Corp is the larger of the two by market cap, and Carnival Corp pays a 1.63% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | CCL | |
|---|---|---|
Market Cap | $30.86B | $37.90B |
Sector | Health | Consumer Cyclical |
52-Week High | $216.63 | $33.99 |
52-Week Low | $132.22 | $23.89 |
Enterprise Value | $37.93B | $61.83B |
Dividend Yield | — | 1.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $210.65, up 3.32% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust fundamentals with a P/E of 37.1 and net income margin of 8.32%, supported by positive cash flow trends. Recent news highlights the acquisition of RayThera Inc. and raised 2026 guidance, reflecting strategic growth initiatives.
Outlook is positive with analyst consensus price target of $234.47, though risks include competitive pressures and earnings volatility. Investment opportunity lies in pipeline expansion and Alzheimer's drug traction, balanced by margin compression concerns from legacy MS portfolio declines.
Carnival Corporation (CCL) trades at $28.42, up 2.49% today, with a bearish technical signal but strong fundamentals. Recent earnings beats and a 59.57% analyst buy rating support optimism. The company shows robust revenue growth, improving net income margins, and positive cash flow in 2025, alongside strategic fleet expansions and sustainability initiatives.
The outlook is positive due to record travel demand and debt reduction, but risks include fuel price volatility and economic sensitivity. With a consensus price target of $35.18, upside potential exists, though technical resistance near $28 may cap near-term gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Carnival Corp
Carnival is the largest global cruise company, with 91 ships in its fleet in October 2022, with eight of its nine brands set to be fully redeployed by the end of 2022. Its portfolio of brands includes Carnival Cruise Lines, Holland America, Princess Cruises, and Seabourn in North America.
Read more on CCL →
